The Non-Coding Landscape of Cutaneous Malignant Melanoma: A Possible Route to Efficient Targeted Therapy

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2020 Nov 18

PMID 33203119

Citations 10

Authors

Andreea D Lazar

Sorina Dinescu

Marieta Costache

Affiliations

Soon will be listed here.

Abstract

Considered to be highly lethal if not diagnosed in early stages, cutaneous malignant melanoma is among the most aggressive and treatment-resistant human cancers, and its incidence continues to rise, largely due to ultraviolet radiation exposure, which is the main carcinogenic factor. Over the years, researchers have started to unveil the molecular mechanisms by which malignant melanoma can be triggered and sustained, in order to establish specific, reliable biomarkers that could aid the prognosis and diagnosis of this fatal disease, and serve as targets for development of novel efficient therapies. The high mutational burden and heterogeneous nature of melanoma shifted the main focus from the genetic landscape to epigenetic and epitranscriptomic modifications, aiming at elucidating the role of non-coding RNA molecules in the fine tuning of melanoma progression. Here we review the contribution of microRNAs and lncRNAs to melanoma invasion, metastasis and acquired drug resistance, highlighting their potential for clinical applications as biomarkers and therapeutic targets.

Citing Articles

New Axes of Interaction in Circ_0079593/miR-516b-5p Network in Melanoma Metastasis Cell Lines.

De Tomi E, Orlandi E, Belpinati F, Patuzzo C, Trabetti E, Gomez-Lira M Genes (Basel). 2025; 15(12.

PMID: 39766913 PMC: 11675925. DOI: 10.3390/genes15121647.

Diagnostic and prognostic role of long non-coding RNAs (lncRNAs) in metastatic melanoma patients with BRAF gene mutation receiving BRAF and MEK inhibitors.

Galus L, Kolenda T, Michalak M, Mackiewicz J Heliyon. 2024; 10(7):e29071.

PMID: 38601651 PMC: 11004874. DOI: 10.1016/j.heliyon.2024.e29071.

BRAF Mutations in Melanoma: Biological Aspects, Therapeutic Implications, and Circulating Biomarkers.

Castellani G, Buccarelli M, Arasi M, Rossi S, Pisanu M, Bellenghi M Cancers (Basel). 2023; 15(16).

PMID: 37627054 PMC: 10452867. DOI: 10.3390/cancers15164026.

Comparative Expression Profiling Reveals Molecular Markers Involved in the Progression of Cutaneous Melanoma towards Metastasis.

Lazar A, Dinescu S, Sleiman L, Dumitru A, Costache M, Costache M Int J Mol Sci. 2023; 24(7).

PMID: 37047539 PMC: 10095431. DOI: 10.3390/ijms24076565.

Genomics and Epigenomics in the Molecular Biology of Melanoma-A Prerequisite for Biomarkers Studies.

Zob D, Augustin I, Caba L, Panzaru M, Popa S, Popa A Int J Mol Sci. 2023; 24(1).

PMID: 36614156 PMC: 9821083. DOI: 10.3390/ijms24010716.

References

Hirota K, Miyoshi T, Kugou K, Hoffman C, Shibata T, Ohta K . Stepwise chromatin remodelling by a cascade of transcription initiation of non-coding RNAs. Nature. 2008; 456(7218):130-4. DOI: 10.1038/nature07348. View

Yu X, Zheng H, Tse G, Chan M, Wu W . Long non-coding RNAs in melanoma. Cell Prolif. 2018; 51(4):e12457. PMC: 6528844. DOI: 10.1111/cpr.12457. View

Pan B, Lin X, Zhang L, Hong W, Zhang Y . Long noncoding RNA X-inactive specific transcript promotes malignant melanoma progression and oxaliplatin resistance. Melanoma Res. 2019; 29(3):254-262. DOI: 10.1097/CMR.0000000000000560. View

Vara-Perez M, Maes H, Van Dingenen S, Agostinis P . BNIP3 contributes to the glutamine-driven aggressive behavior of melanoma cells. Biol Chem. 2018; 400(2):187-193. DOI: 10.1515/hsz-2018-0208. View

Botti G, Scognamiglio G, Aquino G, Liguori G, Cantile M . LncRNA in Tumor Microenvironment: What Role?. Int J Mol Sci. 2019; 20(9). PMC: 6539022. DOI: 10.3390/ijms20092279. View

Stark M, Bonazzi V, Boyle G, Palmer J, Symmons J, Lanagan C . miR-514a regulates the tumour suppressor NF1 and modulates BRAFi sensitivity in melanoma. Oncotarget. 2015; 6(19):17753-63. PMC: 4627343. DOI: 10.18632/oncotarget.3924. View

Noman M, Buart S, Romero P, Ketari S, Janji B, Mari B . Hypoxia-inducible miR-210 regulates the susceptibility of tumor cells to lysis by cytotoxic T cells. Cancer Res. 2012; 72(18):4629-41. DOI: 10.1158/0008-5472.CAN-12-1383. View

Zhao G, Wei Z, Guo Y . MicroRNA-107 is a novel tumor suppressor targeting POU3F2 in melanoma. Biol Res. 2020; 53(1):11. PMC: 7071777. DOI: 10.1186/s40659-020-00278-3. View

Mumford S, Towler B, Pashler A, Gilleard O, Martin Y, Newbury S . Circulating MicroRNA Biomarkers in Melanoma: Tools and Challenges in Personalised Medicine. Biomolecules. 2018; 8(2). PMC: 6022922. DOI: 10.3390/biom8020021. View

10.

Luo C, Weber C, Osen W, Bosserhoff A, Eichmuller S . The role of microRNAs in melanoma. Eur J Cell Biol. 2014; 93(1-2):11-22. DOI: 10.1016/j.ejcb.2014.02.001. View

11.

Valenti R, Huber V, Iero M, Filipazzi P, Parmiani G, Rivoltini L . Tumor-released microvesicles as vehicles of immunosuppression. Cancer Res. 2007; 67(7):2912-5. DOI: 10.1158/0008-5472.CAN-07-0520. View

12.

Shang W, Gao Y, Tang Z, Zhang Y, Yang R . The Pseudogene Promotes the Suppressive Function and Differentiation of Monocytic MDSCs. Cancer Immunol Res. 2019; 7(5):813-827. DOI: 10.1158/2326-6066.CIR-18-0443. View

13.

Gajos-Michniewicz A, Czyz M . Role of miRNAs in Melanoma Metastasis. Cancers (Basel). 2019; 11(3). PMC: 6468614. DOI: 10.3390/cancers11030326. View

14.

Fleming N, Zhong J, Pires da Silva I, Vega-Saenz de Miera E, Brady B, Han S . Serum-based miRNAs in the prediction and detection of recurrence in melanoma patients. Cancer. 2014; 121(1):51-9. PMC: 4270907. DOI: 10.1002/cncr.28981. View

15.

Werner-Klein M, Scheitler S, Hoffmann M, Hodak I, Dietz K, Lehnert P . Genetic alterations driving metastatic colony formation are acquired outside of the primary tumour in melanoma. Nat Commun. 2018; 9(1):595. PMC: 5807512. DOI: 10.1038/s41467-017-02674-y. View

16.

Lambert A, Pattabiraman D, Weinberg R . Emerging Biological Principles of Metastasis. Cell. 2017; 168(4):670-691. PMC: 5308465. DOI: 10.1016/j.cell.2016.11.037. View

17.

Brastianos P, Carter S, Santagata S, Cahill D, Taylor-Weiner A, Jones R . Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discov. 2015; 5(11):1164-1177. PMC: 4916970. DOI: 10.1158/2159-8290.CD-15-0369. View

18.

Wozniak M, Peczek L, Czernek L, Duchler M . Analysis of the miRNA Profiles of Melanoma Exosomes Derived Under Normoxic and Hypoxic Culture Conditions. Anticancer Res. 2017; 37(12):6779-6789. DOI: 10.21873/anticanres.12138. View

19.

Paschen A, Sucker A, Hill B, Moll I, Zapatka M, Nguyen X . Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B. Clin Cancer Res. 2009; 15(16):5208-15. DOI: 10.1158/1078-0432.CCR-09-0886. View

20.

Rambow F, Bechadergue A, Luciani F, Gros G, Domingues M, Bonaventure J . Regulation of Melanoma Progression through the TCF4/miR-125b/NEDD9 Cascade. J Invest Dermatol. 2016; 136(6):1229-1237. DOI: 10.1016/j.jid.2016.02.803. View